Natixis Advisors, L.P. Biogen Inc. Transaction History

Natixis Advisors, L.P.

$53.5 Billion
Q4 2024

A detailed history of Natixis Advisors, L.P. transactions in Biogen Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 16,961 shares of BIIB stock, worth $2.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,961

Previous 24,757 31.49%

Holding current value

$2.39 Million

Previous $4.8 Million 45.95%

% of portfolio

0.0%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	SELL	$146.47 - $191.55 $1.14 Million - $1.49 Million	-7,796 Reduced 31.49%	16,961 $2.59 Million
Q3 2024 Nov 06, 2024	SELL	$189.07 - $236.8 $1.9 Million - $2.38 Million	-10,054 Reduced 28.88%	24,757 $4.8 Million
Q2 2024 Aug 01, 2024	BUY	$190.52 - $236.72 $1.85 Million - $2.3 Million	9,714 Added 38.71%	34,811 $8.07 Million
Q1 2024 Apr 25, 2024	BUY	$212.02 - $267.71 $197,390 - $249,238	931 Added 3.85%	25,097 $5.41 Million
Q4 2023 Feb 06, 2024	BUY	$222.59 - $267.94 $125,763 - $151,386	565 Added 2.39%	24,166 $6.25 Million
Q3 2023 Nov 13, 2023	SELL	$253.3 - $285.89 $1.2 Million - $1.35 Million	-4,720 Reduced 16.67%	23,601 $6.07 Million
Q2 2023 Aug 15, 2023	BUY	$275.25 - $318.06 $492,972 - $569,645	1,791 Added 6.75%	28,321 $8.07 Million
Q1 2023 May 11, 2023	BUY	$256.56 - $292.34 $1.14 Million - $1.29 Million	4,429 Added 20.04%	26,530 $7.38 Million
Q4 2022 Jan 27, 2023	BUY	$252.44 - $306.72 $220,632 - $268,073	874 Added 4.12%	22,101 $6.12 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $657,273 - $906,320	3,376 Added 18.91%	21,227 $5.67 Million
Q2 2022 Aug 12, 2022	BUY	$187.54 - $223.02 $370,016 - $440,018	1,973 Added 12.43%	17,851 $3.64 Million
Q1 2022 May 12, 2022	SELL	$193.77 - $244.14 $100,954 - $127,196	-521 Reduced 3.18%	15,878 $3.34 Million
Q4 2021 Feb 08, 2022	SELL	$223.92 - $287.77 $1.24 Million - $1.59 Million	-5,526 Reduced 25.2%	16,399 $3.94 Million
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $543,340 - $708,576	1,920 Added 9.6%	21,925 $6.2 Million
Q2 2021 Aug 12, 2021	BUY	$259.0 - $414.71 $176,379 - $282,417	681 Added 3.52%	20,005 $6.93 Million
Q1 2021 May 05, 2021	BUY	$242.95 - $284.63 $16,520 - $19,354	68 Added 0.35%	19,324 $5.41 Million
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $16 Million - $24.2 Million	-67,917 Reduced 77.91%	19,256 $4.72 Million
Q3 2020 Nov 12, 2020	BUY	$264.77 - $305.71 $465,200 - $537,132	1,757 Added 2.06%	87,173 $24.7 Million
Q2 2020 Aug 11, 2020	SELL	$258.66 - $342.55 $3.93 Million - $5.21 Million	-15,202 Reduced 15.11%	85,416 $22.9 Million
Q1 2020 Apr 27, 2020	BUY	$268.85 - $341.04 $3.07 Million - $3.9 Million	11,432 Added 12.82%	100,618 $31.8 Million
Q4 2019 Feb 10, 2020	SELL	$220.06 - $304.07 $263,851 - $364,579	-1,199 Reduced 1.33%	89,186 $26.5 Million
Q3 2019 Nov 12, 2019	BUY	$217.44 - $243.88 $1.33 Million - $1.49 Million	6,129 Added 7.27%	90,385 $21 Million
Q2 2019 Aug 12, 2019	BUY	$219.29 - $241.72 $5.48 Million - $6.04 Million	24,999 Added 42.19%	84,256 $19.7 Million
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $2.93 Million - $4.58 Million	-13,524 Reduced 18.58%	59,257 $14 Million
Q4 2018 Feb 13, 2019	SELL	$278.5 - $352.75 $2.47 Million - $3.12 Million	-8,853 Reduced 10.84%	72,781 $21.9 Million
Q3 2018 Nov 13, 2018	BUY	$293.51 - $383.83 $178,747 - $233,752	609 Added 0.75%	81,634 $28.8 Million
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $312,371 - $372,281	1,213 Added 1.52%	81,025 $0
Q1 2018 May 10, 2018	BUY	$260.13 - $367.91 $2.75 Million - $3.89 Million	10,561 Added 15.25%	79,812 $21.9 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $1.39 Million - $1.56 Million	4,519 Added 6.98%	69,251 $22.1 Million
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $18.2 Million - $21.3 Million	64,732	64,732 $20.3 Million

Others Institutions Holding BIIB

# of Institutions

997

Shares Held

131M

Call Options Held

1.77M

Put Options Held

2.34M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.3B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Biogen Inc. Transaction History